Areteia Therapeutics
PrivateLast Round
Series A
Extension
Feb 13, 2024
Total Funding Raised
$425M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Areteia Therapeutics is a biotechnology company that develops oral medications for the treatment of eosinophilic asthma and related inflammatory airway diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Areteia Therapeutics Comparables
Compare Areteia Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Knopp Biosciences | 91% | |
| RAPT Therapeutics | 69% | |
| Roche Holding | 68% |
Areteia Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Feb 13, 2024 | ||||
| Series A | Jul 12, 2022 |
Key People
Founding team and executive leadership
Areteia Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Maverick Capital | Series A, Series A Extension |
| Access Industries | Series A, Series A Extension |
| Bain Capital Life Sciences | Series A, Series A Extension |
| GV | Series A, Series A Extension |
| Maverick Capital | Series A, Series A Extension |
| ARCH Venture Partners | Series A, Series A Extension |
| Viking Global Investors | Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 24, 2026
Monthly visitors increased 62% MoM.
- Mar 26, 2025
Ian F. Smith appointed Chair of the Audit Committee.
Areteia Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Areteia Therapeutics's valuation, stock price, and market status.
Is Areteia a public or private company?
Areteia is a private company.
What is the current stock price of Areteia?
Areteia is a private company with no public stock price. No recent secondary market data is available.
How much is Areteia worth (valuation)?
Valuation information for Areteia is not publicly available.
Can I buy Areteia stock?
Areteia shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Areteia's last funding round?
Areteia's most recent funding round was Series A Extension on February 13, 2024.
Who are the main investors in Areteia?
Key investors in Areteia include Bain Capital Life Sciences.
Will Areteia IPO soon?
No public IPO plans have been announced for Areteia.
How can I track Areteia secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Areteia's secondary market activity and sign up for updates.